We examined the in¯uence of adenovirus-mediated wildtype p16 INK4a (Ad/p16) expression on the radiation sensitivity of NSCLC cell lines, all of which lacked constitutive p16
INK4a but each of which varied in p53 status: A549 (7p16
INK4a
/+pRb/wt-p53), H322 (7p16
/+pRb/mt-p53), and H1299 (7p16 INK4a / +pRb/deleted-p53). The in vitro clonogenic survival results indicate that Ad/p16 enhanced the radiosensitivity of A549 but not H322 or H1299. Further analysis indicated that the apoptosis induced by combination therapy using Ad/p16 plus irradiation was dependent on the endogenous p53 status of the cancer cells. We performed Western blotting to analyse the p53 protein expression of A549 cells treated with either Ad/p16 or Ad/Luc. Endogenous p53 protein levels were higher in A549 cells transfected with Ad/p16 than in those transfected with Ad/Luc. Furthermore, when wt-p53 protein expression was restored in H1299 using Ad/ p53, Ad/p16 stabilized p53 protein expression and radiosensitized the cells. These results suggest that Ad/ p16-induced stabilization of p53 protein may play an important role in Ad/p16 mediated radiosensitization by enhancing or restoring apoptosis properties. Thus, Ad/ p16 plus radiation in combination may be a useful gene therapy strategy for tumors that have wt-p53 but nonfunctional p16
Introduction
Many human tumor cells display abnormalities in one or more genes responsible for regulating cell cycle progression. Such genes include the well-characterized tumor suppressor gene p53, pRb, cyclin D, and p16
INK4a
. Structural alterations of the p53 gene are deleted in about 45 ± 50% of tumors of NSCLC patients (Takahashi et al., 1989) , and are associated with an adverse prognosis (Nishio et al., 1996) . p53 inhibits cell cycle progression in response to various cellular stresses by direct transactivation of p21 WAF1 , an important mediator of cell proliferation, dierentiation, and senescence (el-Deiry et al., 1993; Noda et al., 1994; Xiong et al., 1993) . p21
WAF1 inhibits the ability of cyclin-dependent kinases (CDKs) to phosphorylate pRb, thereby inhibiting cell entry into S phase. Similarly, p16
INK4a inhibits the ability of CDK4 and CDK6 to regulate the phosphorylation status of pRb, thereby also controlling progression into S phase (Lukas et al., 1995; Serrano et al., 1993) . Abnormalities in p16
have been detected in about 70% of NSCLC cell lines, and loss of p16
INK4a protein has been reported in up to 50% of resected primary lung cancer tissue samples (Kratzke et al., 1996; Otterson et al., 1994) . Therefore, restoration of normal function of both p53 and p16
INK4a by gene therapy is an attractive strategy for cancer treatment.
Gene transfer of wild-type p53 has previously been shown to enhance tumor cell radiosensitivity in in vitro and in vivo tumor models (Gallardo et al., 1996; Spitz et al., 1996) . Cellular radiation sensitivity is dependent on cell cycle phase and/or pRb gene product (HaasKogan et al., 1995) among other factors. The regulatory cascade comprising pRb, cyclin D1, CDK4/CDK6, and p16
INK4a plays a central role in cell cycle control, and therefore, may govern radiosensitivity as well. Previous reports have indicated that human tumor cells with wild-type p53 are sensitive to Ad/p16 (Kataoka et al., 2000) , provided that they also contain functional pRb and lack functional p16
INK4a (Craig et al., 1998) . Additionally, p16
INK4a expression restored using an expression vector was associated with increased radiosensitivity in human glioma cell lines with p16
INK4a deletion (Miyakoshi et al., 1997) . The purpose of this study was to determine whether adenovirus mediated p16
INK4a gene transfer enhances radiosensitivity and is a suitable gene replacement therapy in NSCLC. We also examined the apoptosis pathway mediated by combination therapy of Ad/p16 and irradiation.
Results

Ad/p16 enhances radiosensitivity
We ®rst tested whether Ad/p16 infection sensitizes NSCLC cells to irradiation in vitro. Clonogenic assays were performed on three NSCLC lines, A549, H1299, and H322. These lines were infected with either Ad/p16 or Ad/Luc (control vector) and irradiated 48 h later. The 48-h time course was based on preliminary experiments that demonstrated maximum eects in this time frame (data not shown). We assessed cytotoxicity of the vector alone using plating eciency as the endpoint. For all three cell lines, cytotoxicity became evident at MOIs of between 400 and 600 vp/ cell. We then used MOIs of 400, 500, and 600 to assess radiosensitization in further preliminary experiments (data not shown). For A549, the best radiosensitizing eect was seen with 600 vp/cell. We then chose 500 MOI for H322 and H1299, because the cytotoxicity at 500 MOI in these cell lines was similar to that seen in A549 cells with 600 MOI (data not shown).
As shown in Figure 1 , the survival for A549 cells at 2 Gy was reduced from 58.80+1.91 to 33.69+2.84%, and at 4 Gy from 20.69+1.29 to 9.50+1.79% (P50.0167) by Ad/p16. The per cent survival for H1299 cells at 2 Gy was slightly reduced from 74.14+3.55 to 64.81+2.42%, and at 4 Gy from 36.32+2.33 to 27.77+1.20% (Figure 1b ), but these dierences were not statistically signi®cant. The survival curves for H322 were also not dierent between radiation alone and combination therapy in a statistically signi®cant manner. The control vector did not produce a sensitizing eect on its own in any of the cell lines examined in the range of 2 ± 4 Gy.
Apoptotic index analysis
Flow cytometric analysis using APO-BRDU staining was used to measure the level of apoptosis on the basis of TUNEL positivity following various treatments. 
Western blot analysis
To determine the apoptosis pathways enhanced by the combination therapy of Ad/p16 plus irradiation, we analysed various proteins known to be involved in the regulation of apoptosis and the cell cycle by Western blot analysis. Figure 3a ,c,d show that Ad/p16 produced the expression of p16
INK4a and lowered expression of cyclin D1 and pRb within 2 ± 4 days after infection in all cell lines suggesting that this eect occurs independently of endogenous p53 status. In contrast, cyclin D1 and pRb expression were slightly upregulated on day 1, but then returned to control levels after day 2 in A549 cells infected with the control vector Ad/ Luc ( Figure 3b ).
Ad/p16 enhances p53 protein expression
The p53 protein levels dramatically increased starting on day 1 in A549 cells treated with Ad/p16 (Figure 4a ), and, in A549 cells treated with Ad/Luc, they increased on day 3 ( Figure 4b ). As shown in Figure 4c , the p53 protein level in A549 cells treated with Ad/p16 increased sooner and to higher maximum levels than that in Ad/Luc. To con®rm that p53 protein expression was enhanced by Ad/p16 not only in A549 cells, but also other cells that have wt-p53 and wt-pRb, p53 protein expression was examined in H460 cells treated with Ad/p16. The p53 protein level and time course were similar to those seen in A549 cells (data not shown).
Analysis of p53 mRNA by RNase protection assays (RPA)
To further investigate the mechanism by which p53 protein expression is enhanced by Ad/p16 transduction, Figure 1 Clonogenic survival assays to measure radiosensitization by Ad/p16. Six hundred vp/cell was used for the A549 cell line (a), and 500 vp/cell was used for the H1299 (b) and H322 (c) cell lines. Radiation was given 48 h after virus transfection. This time course and vector doses were based on preliminary experiments. Each data point represents the average of three independent experiments. Bar: s.e.
we used a ribonuclease protection assay (RPA) to determine whether induction was the result of an enhanced rate of transcription and whether the p53 protein expression aected the transcription of other . As shown in Figure 5 , transcription of p21 WAF1 mRNA increased in A549 cells treated with Ad/p16 but transcription of p53 mRNA did not.
Ad/p16 stabilizes p53 protein expression
We combined Ad/p16 and Ad/p53 to investigate whether Ad/p16 is capable of stabilizing not only endogenous p53 protein, but also exogenous p53. Ad/ p53 was used at an MOI of 1 vp/cell to simulate physiological levels of wt-p53. This MOI was chosen based on preliminary experiments using Western blot analysis (data not shown). Figure 6 shows p53 and p16
INK4a protein expression in H1299 cells treated with either Ad/Luc alone, Ad/p16 alone, Ad/p53 alone, Ad/ p53 plus Ad/Luc, or Ad/p53 plus Ad/p16. As expected, Ad/p16 produced the expression of p16 INK4a protein; no dierences in expression were observed between Ad/p16 alone and combination therapy using Ad/p16 plus Ad/ p53. Also as expected, neither Ad/Luc nor Ad/p16 alone induced expression of p53, and Ad/p53 induced only a slight expression of p53 protein when used as single agent at an MOI of 1 vp/cell. Ad/Luc did not enhance the p53 protein levels when added to this treatment, but Ad/p16 enhanced the p53 protein levels in comparison to Ad/p53 alone or Ad/p53 plus Ad/Luc.
Combination of Ad/p16 plus Ad/p53 enhances the radiosensitivity of tumor cells lacking wt-p53
We examined the radiosensitizing eects of 1 MOI of Ad/p53 plus either 500 MOI of Ad/p16 or 500 MOI of Ad/Luc in H1299 cells. As shown in Figure 7 , Ad/p53 plus Ad/p16 reduced survival for H1299 cells at 2 Gy from 74.14+3.55 to 49.57+2.56%, and at 4 Gy from 36.32+2.33 to 19.21+3.21% (P50.005). Ad/Luc plus Ad/p53 did not have a sensitizing eect. This phenomenon is similar to that seen for A549 cells in Figure 1 when Ad/p16 was used alone. 
Discussion
Inactivation of p16
INK4a function has been linked to the development of many types of neoplasms, and recent investigations have provided insight regarding the manner in which this inactivation may contribute to cell proliferation (Jin et al., 1996) . There is prior indication in the literature that p16
INK4a
-dependent downmodulation of pRb levels in the presence of overexpressed wild-type p53 causes apoptosis only in tumor cells whereas normal cells arrest in G1 (Sandig et al., 1997) . Here, we compared the abilities of Ad/p16 to radiosensitize NSCLC cell lines that lack p16 INK4a but having either wt-p53, mt-p53, or deleted p53 status. The clonogenic survival results (Figure 1 ) indicated that the A549 cells, which have wt-p53, were substantially radiosensitized by Ad/p16. The NSCLC lines H1299 and H322, which do not have functional p53, were either minimally radiosensitized or not at all. These results were consistent with the analysis of apoptosis by TUNEL (Figure 2) , suggesting that the radiosensitization eect involved a restoration of apoptosis propensity that also depended on the endogenous p53 status of the cells in question. . A549 cells were transfected with either 500 vp/cell of Ad/p16 or Ad/Luc, and radiation (5 Gy) was given 2 days after vector treatment. Two days after irradiation, the cells were harvested and total RNA was extracted using RNAzol TM . Two housekeeping genes, L32 and GAPDH, were used for normalization purposes Figure 6 Western analysis of p53 and p16
INK4a protein in H1299 cells treated with either Ad/Luc alone, Ad/p16 alone, Ad/p53 alone, Ad/p53 plus Ad/Luc, or Ad/p53 plus Ad/p16. Ad/p53 was used at 1 vp/cell, and Ad/p16 or Ad/Luc were used at 500 vp/cell. Vector doses were based on preliminary experiments. Cells were harvested 3 days after treatment Figure 7 Clonogenic survival assays to determine the radiosensitization of Ad/p16 plus Ad/p53. Radiation was given 48 h after transfection. Ad/p53 was used at 1 vp/cell, and Ad/p16 or Ad/Luc were used at 500 vp/cell. Vector doses were based on preliminary experiments. Each data point represents the average of three independent experiments. Bar: s.e.
We examined the underlying mechanism of this phenomenon using Western blot analysis of proteins involved in apoptosis and cell cycle control. Expression of p16
INK4a protein was evident after Ad/p16 transfection in all three cell lines (Figure 3 ). We also found that p53 protein expression levels in A549 cells treated with Ad/p16 were signi®cantly higher than that of controls: a ®vefold dierence was observed on day 2, the time at which radiation would be given in combination with Ad/p16 (Figure 4) . Toxicity of the adenoviral vector backbone has been shown to induce some p53 protein expression in cells that have endogenous wt-p53 (McPake et al., 1999) . Our results with Ad/Luc con®rm that the control vector itself can enhance p53 protein expression; however Ad/p16 enhanced p53 protein expression more quickly and to much higher levels than the control vector (Figure 4) .
We further tested the dependence of radiosensitization on wt-p53 expression in H1299 cells treated with the combination of 1 MOI of Ad/p53 plus 500 MOI of either Ad/p16 or Ad/Luc. The combination of Ad/p53 plus Ad/p16 dramatically enhanced p53 protein expression ( Figure 6 ) and the radiosensitivity of H1299 cells (Figure 7 ) compared to Ad/Luc plus Ad/ p53. Thus, we believe that 1 vp/cell of Ad/p53 in the absence of p16
INK4a produces p53 protein but the level of expression is not sucient to enhance the radiosensitivity of H1299 cells. However, combination therapy using Ad/p53 plus Ad/p16 enhanced radiosensitivity apparently due to Ad/p16's ability to stabilize p53 protein. The p53 protein stabilized by Ad/p16 appears to be functionally active because the transcription of p21 WAF1 was enhanced under this condition in A549 cells ( Figure 5 ). The ribonuclease protection assay showed that no increase in p53 mRNA occurred after Ad/p16 transfection, indicating that an alteration in transcriptional regulation of p53 was not responsible for enhancing the p53 protein expression level in p16
-transduced cells ( Figure 5 ). Thus, p53 protein appears to be stabilized by factors that are aected by p16
INK4a expression. One of these factors may be pRb. It has been previously shown that expression of p16
INK4a in tumor cells induces transcriptional downregulation of the pRb gene (Fang et al., 1998) , which does not depend on the endogenous p53 status of the cell in question; our results ( Figure 3) were consistent with that observation. Haas-Kogen et al. (1995) have shown that pRb is able to suppress radiation-induced apoptosis, and when pRb's function is antagonized, apoptosis proceeds. How pRb regulates apoptosis is not completely understood, but Ad/p16's ability to down-regulate transcription of pRb may lead to p53 protein stabilization and restoration of apoptosis through at least three known pathways. Firstly, Ad/p16 transfection may transiently lead to an increased level of hypophosphorylated pRb in A549 cells (Kataoka et al., 2000) and hypophosphorylated pRb is known to stabilize p53 protein by binding to mdm2 and suppressing its ability to target p53 for degradation (Yap et al., 1999) . Secondly, lowered levels of pRb may release the transcription factor E2F (Nevins, 1992; Weinberg, 1995) . E2F transcriptionally activates p14 ARF which binds to mdm2 and abrogating its function leading to a stabilization of p53 protein (Ashcroft and Vousden, 1999; Sherr and Weber, 2000) . Thirdly, down-regulation of pRb expression by Ad/p16 could also lead to activation of c-Jun N-terminal Kinase (JNK) (Shim et al., 2000) . Non-active JNK targets p53 protein for ubiquitination in an mdm2-independent manner (Fuchs et al., 1998) . Additional studies will have to be performed to determine which one or combination of these mechanisms is responsible for Ad/p16 mediated stabilization of p53 protein and radiosensitization in NSCLC cells.
In summary, we have demonstrated that Ad/p16 infection enhances the radiation sensitivity of NSCLC cells depending on the endogenous wild-type p53 expression of the line. Thus, in combination with radiation, Ad/p16 appears to be a promising gene therapy vector for the treatment of NSCLC because, in those tumors that lack wild-type p53, radiosensitization can still be achieved by adding a very small quantity of Ad/p53 with the Ad/p16. The question arises, however, as to whether Ad/p16 alone or Ad/p16+Ad/p53 is better than radiosensitizing quantities of Ad/p53 used alone. To the extent that we can answer this question, it appears that in A549 cells at least, Ad/p16 produces a dose reduction factor (DRF) of 1.75 when calculated from the survival curves in Figure 1 at the 50% survival level. Similar curves generated using an even higher MOI of Ad/p53 produced a DRF of only 1.37. Therefore, it appears that stabilization of physiological levels of p53 protein through an indirect route is more eective in this context than overexpression of p53 protein by exogenous means. This may be due to dierences in p53 function when it is activated versus when it is overexpressed. The ®ndings reported here indicate that manipulation of the molecular pathways that regulate apoptotic cell death by gene therapy strategies may have ecacy in restoring radiosensitivity to tumor cells that are radioresistant because of defects in apoptosis.
Materials and methods
Cell culture
The human NSCLC cell lines A549, H322, H1299, and H460 were obtained from the American Type Culture Collection (ATCC) and maintained according to their recommendations. The A549 cells and H460 cells have wild-type p53, H322 cells have a point mutation of the p53 gene at codon 248 (G to T) (Mukhopadhyay and Roth, 1993) , and H1299 cells do not have endogenous wild-type p53. None of these lines express endogenous p16
INK4a protein. The similar responses of each line to Ad/p16 with respect to changes in cell cycle kinetics and suppression of cell doubling time have been reported previously (Kataoka et al., 2000) .
Adenovirus production
The recombinant p16
INK4a adenoviral vector (Ad/p16) contains the CMV promoter, wild-type p16
INK4a cDNA, and an SV40 polyadenylation signal in a minigene cassette inserted into the E1-deleted region of modi®ed Ad5. Adenovirusmediated luciferase (Ad/Luc) was used as a control vector. The Ad/p16, Ad/p53, and Ad/Luc vectors were obtained from Introgen Therapeutics Inc. The vectors were tested for and determined to be free of replication-competent viruses.
Gene delivery
In vitro transfection studies for all cell lines were performed by plating 3610 5 cells in T25¯asks. Forty-eight hours after plating, cells were incubated for 1 h with puri®ed vector in 1 ml of medium without serum. Cell numbers for multiplicity of infection (MOI) calculations were determined by counting the cells in an untreated¯ask. After 1 h, fresh medium supplemented with 10% FBS was added to the¯ask. Serumfree medium was used for mock transfection. Cells were further incubated for 48 h before survival curves were set up. The relative infectivity of the cell lines used here for the Ad/p16 vector has been published previously (Kataoka et al., 2000) . The MOIs used in the present experiments were adjusted for each cell line to yield identical reductions in plating eciency. These MOIs, ranging from 500 ± 600 vp/cell produced nearly 100% transfection eciency.
Radiation and clonogenic assay
For in vitro treatments, cells were irradiated with a high-dose rate 137 Cs unit (4.0 Gy/min) at room temperature in a T25 ask. Radiation was given 48 h after vector treatment. The eectiveness of in vitro treatments was assessed by clonogenic assays. Brie¯y, monolayers of A549, H322, and H1299 cells were treated in T25¯asks as described above, given various doses of irradiation, trypsinized, and counted. Known numbers of cells were then replated in 100 mm culture dishes and returned to the incubator to allow macroscopic colony development. The surviving fractions following given treatments were calculated based on the survival of nonirradiated cells treated with either mock infection or vector alone.
Apoptotic index
Apoptosis was quanti®ed by¯ow cytometry using the APO-BRDU TM Kit (PharMingen, San Diego, CA, USA). Brie¯y, 2610 6 cells were ®xed with 1% paraformaldehyde in PBS for 15 min at room temperature, washed twice with PBS, and stored in 70% ethanol at 7208C. For analysis,¯uorescent labeled anti-BrdU antibody solution was added, and the cells incubated in the dark for 30 min at room temperature. The stained cells were analysed by¯ow cytometry with the use of an EPICS¯ow cytometer (Coulter Corp., Hialeah, FL, USA). An analysis region was set based on the negative control, and the percentage of labeled cells was calculated from this region.
Western analysis
Western blot analysis was performed using the ECL Western blotting detection system and protocol (Amersham Corp, Arlington Heights, IL, USA). Brie¯y, cells were scraped from the plates, washed with PBS, and lysed in cell lysis buer. Forty micrograms of protein were electrophoretically separated on SDS-polyacrylamide gels and transferred to polyvinylide di¯uoride membrane (Millipore, Bedford, MA, USA). Mouse monoclonal antibodies for p16 INK4a , pRb, Cyclin D1 (Phamingen, San Diego, CA, USA), and p53 were applied and the membranes were enhanced by chemiluminescence using ECL TM Western blot detection reagents (Amersham Corp) according to the manufacturer's instructions.
Analysis of p53 mRNA by RNase protection assays (RPA) A549 cells were transfected with either Ad/p16 or Ad/Luc, and radiation (5 Gy) was given 2 days after virus transfection. After 2 days of incubation, the cells were washed twice in ice-cold PBS and RNA was extracted using RNAzol TM (TEL-TEST, INC., Friendswood, TX, USA). Probes were labeled with 32 P-UTP and hybridized with the isolated RNA. The probe set used was hCC-2 (PharMingen), which detects p53 and p21
WAF1
. The kit also includes two housekeeping genes, L32 and GAPDH, which are used for sample normalization purposes. After digestion of singlestranded RNA, the protected fragments were separated by PAGE. All steps were performed according to manufacturer's recommendations.
Statistical analysis
ANOVA was used for statistical analysis. Bonferroni correction was used for multiple comparisons between each group. A P value of 0.05 or less was considered statistically signi®cant.
